January 30, 2015
Alejandro Avilés Reyes Receives 2015 Arnold Bleiweis Travel Award
Alejandro Avilés Reyes
Alejandro Avilés Reyes, a graduate student in the Lemos Lab and lab of Jacqueline Abranches, Ph.D., has been selected for the 2015 Arnold Bleiweis Travel Award, to present his work entitled "Modification of Streptococcus mutans Cnm by a novel glycosylation pathway". Mr. Avilés Reyes will give his presentation during the upcoming General Session of the International Association for Dental Research Conference, to be held March 10-14, 2015 in Boston, MA, as part of the first Robert Marquis Mini-Symposium for Young Investigators in Microbiology and Immunology.
Alejandro is currently working on the characterization of Cnm, a collagen-binding protein produced by invasive Streptococcus mutans. The Lemos-Abranches lab focuses on characterization of the stress-response mechanisms of Gram-positive bacteria and their contribution to virulence and disease.
January 13, 2015
Researchers at the University of Rochester Medical Center are testing a new oral vaccine to prevent infection with HIV, the virus that causes AIDS. The vaccine is unique because it is given as a pill, unlike most HIV vaccines tested to date that have been given as shots
The study is funded and designed by Beth Israel Deaconess Medical Center (BIDMC), which received support for a Collaboration for AIDS Vaccine Discovery grant from the Bill & Melinda Gates Foundation. The URMC team and BIDMC are collaborating with the International AIDS Vaccine Initiative, which is helping to organize the study through its Vaccine Product Development Center to provide services to BIDMC grantees. This is one of the first studies to benefit from this partnership and URMC is the only center in the world testing this vaccine.
January 5, 2015
A new $3.8 million grant will bring together clinical and bench researchers to better understand why individuals who receive anti-retroviral treatment for HIV are at greater risk for heart disease and stroke.
The good news is that the drugs being used to fight HIV are increasing life expectancy to normal levels,said University of Rochester neurologist Giovanni Schifitto, M.D., one of the co-leaders of the study.
However, one of the long-term complications is that these treatments, the infection itself, or a combination of the two are increasing risk for cardiovascular and cerebrovascular disease in this population.